If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
22nd Jan 200812:11 pmRNSAcquisition
22nd Jan 200812:00 pmRNSDisposal
21st Dec 20071:22 pmRNSChange of Year End
22nd Oct 20075:57 pmRNSNotification of Shares
10th Oct 20075:29 pmRNSTrading Statement
27th Sep 200712:43 pmRNSNotification of Shares
7th Sep 20071:25 pmRNSNotification of Shares
31st Aug 20075:10 pmRNSOffer Update
31st Aug 20071:53 pmRNSTotal Voting Rights
28th Aug 20074:58 pmRNSAIM Rule 26
22nd Aug 20077:00 amRNSOffer Update
20th Aug 20072:37 pmRNSInterim Results
7th Aug 20075:41 pmRNSOffer Update
7th Aug 20075:29 pmRNSHolding(s) in Company
2nd Aug 20075:43 pmRNSExercise of options
31st Jul 20074:55 pmRNSExercise of Options
27th Jul 20078:00 amRNSIssue of Equity
24th Jul 20075:09 pmRNSOffer Update
24th Jul 20072:49 pmRNSDirector/PDMR Shareholding
24th Jul 20072:47 pmRNSDirector/PDMR Shareholding
24th Jul 20072:46 pmRNSDirector/PDMR Shareholding
24th Jul 20072:45 pmRNSDirector/PDMR Shareholding
24th Jul 20072:42 pmRNSDirector/PDMR Shareholding
23rd Jul 20073:41 pmRNSHolding(s) in Company
23rd Jul 20071:30 pmRNSAGM Statement
20th Jul 200712:08 pmRNSHolding(s) in Company
10th Jul 20072:13 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 20073:03 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 200712:10 pmRNSOffer unconditional
9th Jul 20079:33 amRNSInt Nuclear Solutions
6th Jul 20073:09 pmBUSRule 8.3 - International Nuclear Solutions
5th Jul 20071:51 pmBUSRule 8.3 - International Nuclear Solutions
4th Jul 200712:38 pmBUSRule 8.3 - International Nuclear Solutions
3rd Jul 20072:25 pmBUSRule 8.3 - International Nuclear Solutions
29th Jun 20073:05 pmRNSHolding(s) in Company
28th Jun 200711:44 amRNSHolding(s) in Company
28th Jun 20079:24 amRNSRule 8.1- Intnl Nuclear Sol.
27th Jun 20073:34 pmBUSRule 8.3 - International Nuclear Solutions
25th Jun 20073:18 pmRNSRule 8.1- (Intl Nuclear Sol)
25th Jun 20079:01 amRNSHolding(s) in Company
21st Jun 20072:52 pmBUSRule 8.3 - International Nuclear Solution
21st Jun 20072:34 pmRNSRule 8.3- Int'l Nuclear Sol
20th Jun 20073:19 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
20th Jun 20071:35 pmRNSRule 8.3- Int'l Nuclear Sol.
20th Jun 200710:16 amRNSRule 8.3- Intl Nuclear Sols
20th Jun 200710:02 amRNSRule 8.1- Intl Nuclear Sol
19th Jun 20077:03 amRNSOffer for INS
15th Jun 200711:53 amRNSRule 8.3- Intnl Nuclear
12th Jun 200711:08 amRNSRule 8.3- Intnl Nuclear Sol.
29th May 20073:18 pmBUSRule 8.3 - International Nuclear Solution

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.